Amarin Corporation PLC
AMRN14.750USD
+0.660+4.68%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
306.77MMarket Cap
LossP/E TTM
More Details of Amarin Corporation PLC Company
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Amarin Corporation PLC Info
Ticker SymbolAMRN
Company nameAmarin Corporation PLC
IPO dateApr 01, 1993
CEOBerg (Aaron D)
Number of employees275
Security typeDepository Receipt
Fiscal year-endApr 01
AddressWeWork One Central Plaza Dame Street
CityDUBLIN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIreland
Postal codeD02 K7K5
Phone35316699020
Websitehttps://amarincorp.com/
Ticker SymbolAMRN
IPO dateApr 01, 1993
CEOBerg (Aaron D)
Company Executives of Amarin Corporation PLC
Name
Name/Position
Position
Shareholding
Change
Dr. David Keenan, Ph.D.
Dr. David Keenan, Ph.D.
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
11.71K
+3758.00%
Dr. Paul Cohen, M.D.
Dr. Paul Cohen, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
401.00
+401.00%
Ms. Diane E. Sullivan
Ms. Diane E. Sullivan
Non-Executive Independent Director
Non-Executive Independent Director
401.00
+401.00%
Mr. Oliver O'Connor
Mr. Oliver O'Connor
Non-Executive Independent Director
Non-Executive Independent Director
401.00
+401.00%
Dr. Stephen B. (Steven) Ketchum, Ph.D.
Dr. Stephen B. (Steven) Ketchum, Ph.D.
President - Research and Development, Executive Vice President, Chief Scientific Officer
President - Research and Development, Executive Vice President, Chief Scientific Officer
--
--
Mr. Aaron D. Berg
Mr. Aaron D. Berg
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Patrice Bonfiglio
Ms. Patrice Bonfiglio
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Keith L. Horn
Mr. Keith L. Horn
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Odysseas D. Kostas, M.D.
Dr. Odysseas D. Kostas, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Louis Sterling, III
Mr. Louis Sterling, III
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. David Keenan, Ph.D.
Dr. David Keenan, Ph.D.
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
11.71K
+3758.00%
Dr. Paul Cohen, M.D.
Dr. Paul Cohen, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
401.00
+401.00%
Ms. Diane E. Sullivan
Ms. Diane E. Sullivan
Non-Executive Independent Director
Non-Executive Independent Director
401.00
+401.00%
Mr. Oliver O'Connor
Mr. Oliver O'Connor
Non-Executive Independent Director
Non-Executive Independent Director
401.00
+401.00%
Dr. Stephen B. (Steven) Ketchum, Ph.D.
Dr. Stephen B. (Steven) Ketchum, Ph.D.
President - Research and Development, Executive Vice President, Chief Scientific Officer
President - Research and Development, Executive Vice President, Chief Scientific Officer
--
--
Mr. Aaron D. Berg
Mr. Aaron D. Berg
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Sarissa Capital Management, L.P.
5.98%
Kynam Capital Management LP
2.77%
Acadian Asset Management LLC
2.20%
Morgan Stanley & Co. LLC
1.21%
Eversept Partners, LP
0.80%
Other
87.04%
Shareholders
Shareholders
Proportion
Sarissa Capital Management, L.P.
5.98%
Kynam Capital Management LP
2.77%
Acadian Asset Management LLC
2.20%
Morgan Stanley & Co. LLC
1.21%
Eversept Partners, LP
0.80%
Other
87.04%
Shareholder Types
Shareholders
Proportion
Hedge Fund
12.07%
Investment Advisor
3.02%
Investment Advisor/Hedge Fund
2.88%
Research Firm
1.93%
Individual Investor
1.05%
Pension Fund
0.30%
Family Office
0.24%
Other
78.52%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
291
4.18M
22.49%
+4.06K
2025Q3
314
4.20M
24.13%
+467.66K
2025Q2
330
3.80M
23.58%
+94.36K
2025Q1
338
3.76M
23.88%
-1.19M
2024Q4
355
3.75M
23.57%
+236.09K
2024Q3
360
3.51M
29.65%
-554.68K
2024Q2
386
4.06M
34.43%
-548.92K
2024Q1
399
4.62M
36.64%
-2.90M
2023Q4
416
4.89M
38.80%
+197.93K
2023Q3
435
4.67M
42.33%
-650.41K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Sarissa Capital Management, L.P.
1.24M
5.98%
--
--
Sep 30, 2025
Kynam Capital Management LP
576.11K
2.77%
--
--
Sep 30, 2025
Acadian Asset Management LLC
456.58K
2.2%
+215.53K
+89.41%
Sep 30, 2025
Morgan Stanley & Co. LLC
251.41K
1.21%
+104.14K
+70.72%
Sep 30, 2025
Eversept Partners, LP
167.28K
0.8%
--
--
Sep 30, 2025
WaterFront Wealth, Inc.
77.96K
0.37%
-16.77K
-17.70%
Sep 30, 2025
Millennium Management LLC
132.39K
0.64%
+87.15K
+192.62%
Sep 30, 2025
Citadel Advisors LLC
122.29K
0.59%
+76.83K
+169.03%
Sep 30, 2025
SCP Investment, LP
100.00K
0.48%
-25.00K
-20.00%
Sep 30, 2025
BNP Paribas Securities Corp. North America
87.37K
0.42%
+11.43K
+15.04%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.03%
SPDR S&P International Small Cap ETF
0.02%
Global X Aging Population ETF
0%
ActivePassive International Equity ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
ProShares Ultra Nasdaq Biotechnology
Proportion0.04%
Invesco Nasdaq Biotechnology ETF
Proportion0.03%
SPDR S&P International Small Cap ETF
Proportion0.02%
Global X Aging Population ETF
Proportion0%
ActivePassive International Equity ETF
Proportion0%
Invesco NASDAQ Future Gen 200 ETF
Proportion0%
SPDR Portfolio Developed World ex-US ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Mar 12, 2025
Merger
20→1
Mar 12, 2025
Merger
20→1
Date
Ex-dividend Date
Type
Ratio
Mar 12, 2025
Merger
20→1
Mar 12, 2025
Merger
20→1
